SE448679B - Infusionslosning for patienter med cancer innehallande essentiella aminosyror men er fri fran metionin - Google Patents
Infusionslosning for patienter med cancer innehallande essentiella aminosyror men er fri fran metioninInfo
- Publication number
- SE448679B SE448679B SE7907316A SE7907316A SE448679B SE 448679 B SE448679 B SE 448679B SE 7907316 A SE7907316 A SE 7907316A SE 7907316 A SE7907316 A SE 7907316A SE 448679 B SE448679 B SE 448679B
- Authority
- SE
- Sweden
- Prior art keywords
- cancer
- amino acid
- solution
- free
- amino acids
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 49
- 201000011510 cancer Diseases 0.000 title claims description 34
- 239000003978 infusion fluid Substances 0.000 title claims description 21
- 235000020776 essential amino acid Nutrition 0.000 title claims description 9
- 239000003797 essential amino acid Substances 0.000 title claims description 9
- 239000000243 solution Substances 0.000 claims description 46
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 20
- 239000004471 Glycine Substances 0.000 claims description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 9
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 9
- 239000004473 Threonine Substances 0.000 claims description 9
- 229960000310 isoleucine Drugs 0.000 claims description 9
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 9
- 229930182817 methionine Natural products 0.000 claims description 9
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 9
- 235000008729 phenylalanine Nutrition 0.000 claims description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- 235000004279 alanine Nutrition 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- 235000004400 serine Nutrition 0.000 claims description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 6
- 235000002374 tyrosine Nutrition 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 4
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 229960003104 ornithine Drugs 0.000 claims description 4
- 235000013930 proline Nutrition 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 description 46
- 235000001014 amino acid Nutrition 0.000 description 46
- 150000001413 amino acids Chemical class 0.000 description 46
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 32
- 241000700159 Rattus Species 0.000 description 24
- 239000000203 mixture Substances 0.000 description 18
- 206010039491 Sarcoma Diseases 0.000 description 12
- 230000037213 diet Effects 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000001802 infusion Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- 208000009916 Yoshida Sarcoma Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229960005190 phenylalanine Drugs 0.000 description 6
- 229960002898 threonine Drugs 0.000 description 6
- 229960004799 tryptophan Drugs 0.000 description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229960003136 leucine Drugs 0.000 description 5
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 235000021476 total parenteral nutrition Nutrition 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 229960003121 arginine Drugs 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 229960003646 lysine Drugs 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
- 229960004295 valine Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 239000011833 salt mixture Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- -1 Sucrose Vitamin Chemical class 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229960003589 arginine hydrochloride Drugs 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 238000013110 gastrectomy Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 2
- 208000001297 phlebitis Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000012711 vitamin K3 Nutrition 0.000 description 2
- 239000011652 vitamin K3 Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 229940041603 vitamin k 3 Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229950009268 zinostatin Drugs 0.000 description 2
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- KXEASOROAFAOHX-ZAHKZPOQSA-N 4-methoxy-6-[(e)-2-[4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]ethenyl]pyran-2-one Chemical compound O1C(=O)C=C(OC)C=C1\C=C\C(C=C1)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 KXEASOROAFAOHX-ZAHKZPOQSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000003609 Bile Duct Adenoma Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- LHZDKNLVYWYRSS-UHFFFAOYSA-N panamin Natural products C1CCC(NC1)C23CC(CC4CCCN=C24)C5CCCCN5C3 LHZDKNLVYWYRSS-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10874978A JPS5535049A (en) | 1978-09-04 | 1978-09-04 | Amino acid transfusion for cancerous patient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7907316L SE7907316L (sv) | 1980-03-05 |
| SE448679B true SE448679B (sv) | 1987-03-16 |
Family
ID=14492527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7907316A SE448679B (sv) | 1978-09-04 | 1979-09-03 | Infusionslosning for patienter med cancer innehallande essentiella aminosyror men er fri fran metionin |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JPS5535049A (cs) |
| AU (1) | AU526207B2 (cs) |
| CA (1) | CA1134275A (cs) |
| CH (1) | CH642541A5 (cs) |
| DE (1) | DE2935709C2 (cs) |
| FR (1) | FR2434622A1 (cs) |
| GB (1) | GB2029220B (cs) |
| IT (1) | IT1194844B (cs) |
| NL (1) | NL190266C (cs) |
| SE (1) | SE448679B (cs) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58500526A (ja) * | 1981-04-17 | 1983-04-07 | アメリカン ホスピタル サプライ コ−ポレ−シヨン | 非経口栄養供給のための改良溶液 |
| FR2508797B1 (fr) * | 1981-07-03 | 1986-03-14 | Charles Chany | Medicament comprenant le produit de la reaction d'un acide carboxylique en c1 a c6 sur un amino-acide basique |
| DE3329253A1 (de) * | 1983-08-12 | 1985-02-21 | Milupa Ag, 6382 Friedrichsdorf | Verwendung eines aminosaeuregemisches zur bekaempfung insbesondere von lymphadenomen |
| HU191598B (en) * | 1984-03-20 | 1987-03-30 | Egyt Gyogyszervegyeszeti Gyar | Method for the preparation of injection solution suitable preferably against cathosis |
| DE3440090A1 (de) * | 1984-11-02 | 1986-05-07 | Novo-Med AG, Appenzell | Aminosaeureloesungen enthaltendes arzneimittel zur therapie von krebserkrankungen und verfahren zu seiner herstellung |
| IL77629A (en) * | 1985-01-22 | 1989-07-31 | Abbott Lab | High fat,low carbohydrate enteral nutritional for mula |
| FR2591893B1 (fr) * | 1985-12-19 | 1988-11-10 | Centre Nat Rech Scient | Compositions nutritionnelles carencees en methionine destinees a inhiber le developpement et la dissemination des tumeurs malignes chez les mammiferes |
| US5162373A (en) * | 1986-01-17 | 1992-11-10 | Board Of Regents, The University Of Texas System | Methods and improved formulations for the determination and treatment of malignant disease in patients |
| US5189025A (en) * | 1988-12-09 | 1993-02-23 | Board Of Regenets, The University Of Texas System | Methods for the treatment of malignant disease in patients using citrulline containing amino acid solutions |
| GB8917660D0 (en) * | 1989-08-02 | 1989-09-20 | Rana Ashok S J | Prophylaxis of transurethral resection reactions |
| US5658895A (en) * | 1991-10-07 | 1997-08-19 | Otsuka Pharmaceutical Factory, Inc. | Anticancer enteral feeding composition |
| KR0172193B1 (ko) * | 1991-10-07 | 1999-02-01 | 오오쓰까 아끼히꼬 | 암 치료용 경장제제 |
| DE4228897A1 (de) * | 1992-08-29 | 1994-03-03 | Wella Ag | Mittel zur Festigung der Haare auf der Basis von Lignin oder Ligninderivaten sowie Dihydroxypropyllignin |
| DE69334292D1 (de) * | 1992-11-19 | 2009-10-08 | Anticancer Inc | Verwendung von Methioninase als Antitumormittel in der Antimethionin-chemotherapie |
| HU213677B (en) * | 1993-11-09 | 1997-12-29 | Immunal Kft | Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them |
| RU2125874C1 (ru) * | 1994-07-04 | 1999-02-10 | Казанский государственный университет им.В.И.Ульянова-Ленина | Композиция аминокислот с микроэлементами, обладающая противоопухолевой и антигипоксической активностью |
| WO1998004255A1 (en) * | 1996-07-30 | 1998-02-05 | Novartis Nutrition Ag | Amino acid composition and use thereof in treating tumor growth and metastasis |
| EP1068868A3 (en) * | 1997-07-08 | 2001-01-31 | Rath, Matthias, Dr. med. | Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration |
| RU2144821C1 (ru) * | 1999-02-16 | 2000-01-27 | Товарищество с ограниченной ответственностью Фирма "ГЛЕС" | Противоопухолевое средство |
| ES2258426T3 (es) * | 2000-06-16 | 2006-09-01 | Matthias Dr. Med. Rath | Composicion para la prevencion de enfermedades de los musculos lisos que comprenden ascorbato, arginina y magnesio. |
| DE60028376T2 (de) * | 2000-10-09 | 2007-06-06 | Rath, Matthias, Dr. | Therapeutische Kombination des Ascorbats mit Lysin und Arginin für Verhinderung und Behandlung des Krebses |
| US6974833B2 (en) | 2001-01-16 | 2005-12-13 | Matthias Rath | Synergistic compositions comprising ascobate and lysine for states related to extra cellular matrix degeneration |
| US6686340B2 (en) | 2001-06-19 | 2004-02-03 | Matthias Rath | Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells |
| SG106614A1 (en) * | 2001-06-21 | 2004-10-29 | Matthias Rath Dr | Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body |
| JPWO2003030890A1 (ja) * | 2001-10-05 | 2005-02-10 | 哲朗 浅尾 | 免疫系活性化剤 |
| US20030105104A1 (en) * | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| US20050053664A1 (en) | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| WO2005092097A1 (en) * | 2004-03-19 | 2005-10-06 | Pro-Pharmaceuticals, Inc. | Compositions and methods for targeting metastatic tumors using multivalent ligand-linked carbohydrate polymers |
| WO2007016951A1 (en) * | 2005-07-29 | 2007-02-15 | Matuschka-Greiffenclau Markus | Composition for reducing the risc of alcohol induced pancreatic cancer |
| WO2007016949A1 (en) * | 2005-07-29 | 2007-02-15 | Matuschka-Greiffenclau Markus | Composition for reducing the risc of alcohol induced neuropathy |
| WO2007016954A1 (en) * | 2005-07-29 | 2007-02-15 | Matuschka-Greiffenclau Markus | Composition for reducing drug or alcohol induced breast cancer risk |
| WO2007016950A1 (en) * | 2005-07-29 | 2007-02-15 | Matuschka-Greiffenclau Markus | Composition for reducing the risk of alcohol induced neurodegenerative disease |
| WO2007016955A1 (en) * | 2005-07-29 | 2007-02-15 | Matuschka-Greiffenclau Markus | Alcohol metabolism moderating composition |
| ATE554663T1 (de) * | 2005-07-29 | 2012-05-15 | Tima Foundation | Zusammensetzung zur steuerung des alkohol metabolismus und zur reduktion des risikos von alkoholbedingten krankheiten |
| WO2007016952A1 (en) * | 2005-07-29 | 2007-02-15 | Matuschka-Greiffenclau Markus | Composition for reducing the risk of alcohol induced esophagenal and oropharyngolaryngeal cancer |
| US8865646B2 (en) | 2007-03-28 | 2014-10-21 | University Of South California | Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging |
| WO2008119077A1 (en) | 2007-03-28 | 2008-10-02 | University Of Southern California | Induction of differential stress resistance and uses thereof |
| WO2009132320A2 (en) | 2008-04-24 | 2009-10-29 | University Of Southern California, Usc Stevens | Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging |
| CN103347511B (zh) * | 2011-02-17 | 2016-04-27 | 味之素株式会社 | 化学治疗剂的抗肿瘤活性的增强剂 |
| JP2016117702A (ja) * | 2014-12-22 | 2016-06-30 | 武輝 山田 | ガン細胞の死滅法 |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| WO2019036471A1 (en) | 2017-08-14 | 2019-02-21 | Axcella Health Inc. | AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE |
| US10596136B2 (en) | 2018-06-20 | 2020-03-24 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| IT202000000454A1 (it) * | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT297935B (de) * | 1968-05-09 | 1972-04-10 | Astra Ab | Verfahren zur Herstellung einer Infusionslösung von essentiellen Aminosäuren zur intravenösen Zufuhr bei urämischen Zuständen |
| SU423304A3 (cs) * | 1970-03-10 | 1974-04-05 | Тейзо Хигаси, Дзинносуке Лбе, Теруо Таке, Сусуми Ватанабе , Масару Отани | |
| DE2013026C3 (de) * | 1970-03-19 | 1981-01-29 | Wagner, Karl-Heinz, Prof. Dr.Med.Habil., 6300 Giessen | Mittel zur Behandlung und Verhütung von Leberkrankheiten und muskulärer Insuffizienz |
| DE2530246A1 (de) * | 1975-07-07 | 1977-01-13 | Fresenius Chem Pharm Ind | L-aminosaeuregemische fuer parenterale oder orale anwendung |
| DE2531204C2 (de) * | 1975-07-12 | 1987-01-22 | Fresenius AG, 6380 Bad Homburg | L-Aminosäuregemische für die parenterale oder orale Ernährung |
-
1978
- 1978-09-04 JP JP10874978A patent/JPS5535049A/ja active Granted
-
1979
- 1979-08-28 GB GB7929789A patent/GB2029220B/en not_active Expired
- 1979-08-29 AU AU50368/79A patent/AU526207B2/en not_active Expired
- 1979-08-31 CA CA334,841A patent/CA1134275A/en not_active Expired
- 1979-09-03 FR FR7921975A patent/FR2434622A1/fr active Granted
- 1979-09-03 IT IT05216/79A patent/IT1194844B/it active
- 1979-09-03 SE SE7907316A patent/SE448679B/sv not_active IP Right Cessation
- 1979-09-04 DE DE2935709A patent/DE2935709C2/de not_active Expired
- 1979-09-04 CH CH799179A patent/CH642541A5/de not_active IP Right Cessation
- 1979-09-04 NL NLAANVRAGE7906620,A patent/NL190266C/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2434622A1 (fr) | 1980-03-28 |
| NL190266B (nl) | 1993-08-02 |
| AU526207B2 (en) | 1982-12-23 |
| JPS6154007B2 (cs) | 1986-11-20 |
| CH642541A5 (de) | 1984-04-30 |
| JPS5535049A (en) | 1980-03-11 |
| IT1194844B (it) | 1988-09-28 |
| DE2935709A1 (de) | 1980-03-13 |
| AU5036879A (en) | 1980-03-13 |
| DE2935709C2 (de) | 1986-02-06 |
| GB2029220A (en) | 1980-03-19 |
| SE7907316L (sv) | 1980-03-05 |
| NL7906620A (nl) | 1980-03-06 |
| IT7905216A0 (it) | 1979-09-03 |
| FR2434622B1 (cs) | 1983-04-15 |
| NL190266C (nl) | 1994-01-03 |
| GB2029220B (en) | 1983-03-30 |
| CA1134275A (en) | 1982-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE448679B (sv) | Infusionslosning for patienter med cancer innehallande essentiella aminosyror men er fri fran metionin | |
| Laszlo et al. | Effects of glucose analogues (2-deoxy-D-glucose, 2-deoxy-D-galactose) on experimental tumors | |
| Czyzyk et al. | Effect of biguanides on intestinal absorption of glucose | |
| KR100861889B1 (ko) | 중환자, 만성 질환자 및 영양실조인 사람의 비경구 영양공급 또는 부분 장내/경구 영양 공급을 위해 장내투여되는 보충제 | |
| JP6130666B2 (ja) | １種以上のクレアチン化合物を含んでなる血液透析液及び腹膜透析液 | |
| DE69607750T2 (de) | Aminosäurenzusammensetzungen und verwendung derselben klinischen nährung | |
| GB2113524A (en) | Elemental diets for liver diseases | |
| EP0547099B1 (en) | Product containing growth factor and glutamine and use of growth factor for the treatment of intestinal mucosa | |
| US11129843B2 (en) | Treating and preventing kidney damage | |
| SE464796B (sv) | Komposition avsedd att minska oeverviktstillstaand hos daeggdjur innehaallande pyruvat och dihydroxiaceton | |
| SE521049C2 (sv) | Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa | |
| KR20180101460A (ko) | 근육의 보호에서 시스탄케 투불로사 추출물 및 이소악테오사이드의 용도 | |
| JPH10130153A (ja) | 大腸癌、食道癌及び乳癌より選ばれた癌に用いる 抗悪性腫瘍剤 | |
| US6797729B1 (en) | Therapeutic glutamine and N-actyl-cysteine composition | |
| JP2648176B2 (ja) | 制癌剤 | |
| JP5065555B2 (ja) | コリン配合輸液剤 | |
| US5008287A (en) | Pharmaceutical compositions having antineoplastic activity | |
| EP0348664A2 (en) | Pharmaceutical compositions containing monoacetoacetins for treating tumours | |
| EP1062946A1 (en) | Preventives and remedies for intestinal mucosal disorder | |
| JPH0534338B2 (cs) | ||
| MXPA97006140A (en) | Compositions of amino acids and the use of them in nutrition clin | |
| Munder | Lysolecithin and its analogs | |
| HK1164157B (en) | Hemodialysis and peritoneal dialysis solutions comprising one or more creatine compounds | |
| JPH05186354A (ja) | 抗癌剤及び免疫賦活剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 7907316-9 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 7907316-9 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 7907316-9 Format of ref document f/p: F |